← GT Biopharma, Inc. (GTBP) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
GT Biopharma, Inc. (GTBP)
Pharmaceutical Preparations · market cap $12M · as of 2026-07-18
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-13 (est.)
Earnings
Pipeline
0
programs
Upcoming events
1
next 90d+
Dossier
Ready
cached
GT Biopharma, Inc. (GTBP) is a micro-cap pharmaceutical company with a market cap of approximately $13M and a single disclosed asset: Temozolomide in Phase 3 development for Glioblastoma. The company has 1 employee, $8.9M in cash providing roughly 10.8 months of runway, and no upcoming catalysts on the calendar.
The catalyst path
- 2026-11-13 (est.)Earningsimp 5/10
Pipeline
No pipeline data.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for GTBP (10-K, 10-Q, S-3, 13D/G, Form 4)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.